This is the text extract for 2009/10 funding options before PHARMAC that were not funded, browse documents here.

---

Funding options that PHARMAC had before it during 2009/10 that were not funded (implemented) during that year

These options comprise any proposal for funding potentially under consideration by PHARMAC at any stage between 1 July 2009 and 30 June 2010 that were not funded during that time. The list includes any funding proposals that were under active consideration; assessed but not under active consideration; recommended decline by PTAC; undergoing assessment (therefore not yet prioritised); waiting for clinical information (e.g. PTAC review) before they could be further progressed; and approved in 2009/10 but not funded until 2010/11. The list includes all funding proposals received by PHARMAC since 2008 (which will also be included in the web application tracker). All efforts have been made to include all historic funding proposals received before then, but some of these may inadvertently not have been included. The patient population is an estimate of the number of people to be treated with the medicine (often provided by the applicant), and is expressed as a broad range. The range does not take into account any possible targeting mechanisms that may apply should a funding decision be made.

Pharmaceutical Abacavir/lamivudine/zidovudine Adapalene PKU Supplementation (Add-ins) Adrenaline Auto-injector Agalsidase alfa Alemtuzumab Alglucosidase alfa (Myozyme) Aliskiren Aminioacid Formula without phenylalanine (PKU Anamix Junior LQ) Atomoxetine Azacitidine Bevacizumab

Funding Requested For HIV infection Acne - first line Phenylketonuria (PKU) Anaphylaxis Fabry disease (a-galactosidase A deficiency) - Enzyme replacement therapy (ERT) Chronic lymphocytic leukemia - third line Pompe's disease Hypertension Phenylketonuria (PKU) Attention Deficit Hyperactivity Disorder (ADHD) - increased access Myelodysplastic syndromes Metastatic colorectal cancer - first line

Patient Population 1,000-10,000 10,000-50,000 100-1000 1,000-10,000 <100 <100 <100 50,000+ <100

10,000-50,000 100-1000 100-1000

1

---

Pharmaceutical Bevacizumab Bimatoprost 0.03% and timolol maleate 0.5% Bortezomib Bortezomib Bortezomib Brimonidine Tartrate 0.15% Budesonide

Funding Requested For Metastatic colorectal cancer confined to the liver Open-angle glaucoma (OAG) or ocular hypertension (OHT) Induction therapy Multiple Myeloma, Relapsed refractory second line Multiple Myeloma in patients ineligible for stem cell transplant - first line Glaucoma Crohn's disease (steroid dependency and longer SA period); and gut Graft vs. Host disease. Crohn's disease - patients with psychiatric problems and patients with relapse during pregnancy Microscopic colitis Asthma Persistent moderate to severe pain Detoxification and maintenance treatment of opioid dependence Psoriasis Heart Failure (widening access to allow combination with an ACEi) Adjuvant high risk stage II colorectal cancer Neoadjuvant rectal cancer Secondary hyperparathyroidism Chronic suppurative otitis media Transient Ischemic Attack (TIA) - high risk patients Stroke + Transient Ischemic Attack (TIA) - alternative to aspirin and dipyridamole combo therapy Acute Coronary Syndrome (ACS) widening access to 12 months (from 3 months) Drug-Eluting Stents (DES) - widening access to 12 months (from 6 months) Cardio vascular disease - Widening of access to include patients intolerant to aspirin Haemophilia with arthropathy

Patient Population 100-1000 1,000-10,000 100-1000 100-1000 100-1000 10,000-50,000 100-1000

Budesonide (Entocort CIR) Budesonide (Entocort CIR) Budesonide with eformoterol Buprenorphine patches Buprenorphine/naloxone Calcipotriol and betamethasone Candesartan Capecitabine Capecitabine Cinacalcet hydrochloride Ciprofloxacin and hydrocortisone ear drops Clopidogrel Clopidogrel

100-1000 100-1000 50,000+ 100-1000 1,000-10,000 10,000-50,000 1,000-10,000 100-1000 100-1000 <100 10,000-50,000 1,000-10,000 1,000-10,000

Clopidogrel

1,000-10,000

Clopidogrel

1,000-10,000

Clopidogrel Cox 2 inhibitors

1,000-10,000 100-1000

2

---

Pharmaceutical Dabigatran Dabigatran Darunavir Darunavir Dasatinib

Funding Requested For Stroke, systemic embolism, atrial fibrillation Prevention of venous thrombosis following orthopaedic surgery HIV infection (patients who have failed at least 3 antiretroviral regimens) HIV infection Bridge to allogenic transplant in patients with a defined donor Congenital anaemia with resulting chronic iron overload in patients (all ages) contraindicated to desferrioxamine Congenital anaemia with resulting chronic iron overload in patients (all ages) intolerant to desferrioxamine Congenital anaemia with resulting chronic iron overload in patients (all ages) contraindicated to desferrioxamine Congenital anaemia with resulting chronic iron overload in patients (all ages) intolerant to desferrioxamine Contraception Stroke prophylaxis Stroke prophylaxis Early breast cancer Alzheimer's disease (Dementia) Cystic fibrosis - widening of access FEV1</= 75% predicted Treatment-resistant major depression Cow’s milk protein allergy, food intolerance and hypersensitivity Food allergies Non-Small Cell Lung Cancer (NSCLC) Anaemia in cancer patients Depression HIV infection (patients who have failed at least 3 antiretroviral regimens) Prevention of rejection of renal/cardiac transplants

Patient Population 10,000-50,000 1,000-10,000 100-1000 1,000-10,000 <100

Deferasirox

<100

Deferasirox

<100

Deferiprone

<100

Deferiprone Desogestrel Dipyridamole 200mg Dipyridamole 200mg + aspirin Docetaxel Donepezil Dornase Alfa Duloxetine Elemental Formula (Alfare) Elemental Formula (Neocate Nutra) Erlotinib Erythropoietin Escitalopram Etravirine Everolimus

<100 50,000+ 1,000-10,000 1,000-10,000 100-1000 10,000-50,000 100-1000 1,000-10,000 1,000-10,000 1,000-10,000 <100 100-1000 10,000-50,000 <100 <100

3

---

Pharmaceutical Exenatide Ezetimibe Female condoms Fentanyl low dose patches Folic Acid Food Thickeners Fulvestrant Galantamine Gefitinib Gemcitabine Gemcitabine Gemfibrozil Gluten free foods Gluten free Gluten Gluten Free Multi-seed bread mix (Bakels) Golimumab Golimumab Golimumab High dose fluticasone/salmeterol Homocystinuria (HCU) Cooler Hydrolysed rice protein formula (Risolac) Idursulfase

Funding Requested For Type 2 diabetes Hyperlipidemia (add-on to atorvastatin) STI prevention and contraception Pain Supplementation in pregnancy (0.4mg to replace 0.8mg tablet) Dysphagia Locally advanced or metastatic breast cancer - third line Alzheimer's disease (Dementia) Non Small Cell Lung Cancer (NSCLC) Pancreatic cancer Locally advanced or metastatic cholangiocarcinoma Hypercholesterolemia patients intolerant to statins Amendment to SA biopsy requirement Coeliac disease Coeliac disease Rheumatoid arthritis - second-line TNF inhibitor Psoriatic Arthritis - second line TNF Inhibitor Ankylosing spondylitis - second line TNF Inhibitor Asthma and COPD Homocystinuria Cows milk protein intolerance Hunter syndrome (Mucopolysaccharidosis II, MPS II) Enzyme replacement therapy (ERT) Gastrointestinal Stromal Tumor (GIST), C-kit Negative Chronic myelogenous leukemia (CML) allow doses higher than 400mg (600mg max) Actinic keratosis Type 1 diabetes Type 1 diabetes - second line LA insulin

Patient Population 100-1000 10,000-50,000 50,000+ 100-1000 10,000-50,000 1,000-10,000 <100 10,000-50,000 <100 100-1000 <100 100-1000 10,000-50,000 1,000-10,000 1,000-10,000 100-1000 100-1000 100-1000 1,000-10,000 <100 1,000-10,000

<100

Imatinib Imatinib Imiquimod Insulin aspart 30/70 Insulin detemir

<100 <100 50,000+ 1,000-10,000 100-1000

4

---

Pharmaceutical Interferon beta-1-a (rch) Iodine Isopropyl alcohol 95% and anhydrous glcerin 5% Ketamine Ketogenic diet formula (Ketocal) Ketotifen fumarate Lacosamide Lanreotide Lapatinib

Funding Requested For Multiple Sclerosis (MS) - relapsingremitting Supplementation for pregnancy and breast feeding Swimmers ear Palliative care patients with intractable pain not adequately controlled with opioids. Chronic intractable epilepsy Treatment of ocular allergy Epilepsy Acromegaly and Neuroendocrine tumours Advanced/metastatic HER-2 positive breast cancer Mucopolysaccharidosis I (MPS I) to treat the non-neurological manifestations Enzyme replacement therapy (ERT) Glaucoma Prevention of STI transmission Multiple Myeloma Helicobacter pylori- 2nd line use Long acting reversible contraception Long acting reversible contraception Gout Nausea and vomiting Bacterial vaginosis Depression, treatment-resistant Premature infants Narcolepsy - last-line treatment Narcolepsy - open listing Crohn's Disease Asthma - aspirin induced (AIA) Asthma - exercise induced (EIA) Asthma - patients intolerant to ihhaled corticosteroids Asthma - preschool wheeze Multiple Sclerosis (MS) - Amending entry criteria Multiple Sclerosis (MS) - Removal of exit criteria Multiple Sclerosis (MS) - Amending exit criteria

Patient Population 1,000-10,000 50,000+ 10,000-50,000 100-1000 <100 <100 100-1000 100-1000 <100

Laronidase Latanoprost with timolol Latex oral dams Lenalidomide levofloxacin Levonorgestrel Implants levonorgestrel Intraurine system Losartan Metoclopramide oral liquid Metronidazole Mianserin Milk substitute formula (S-26 Gold) Modafinil Modafinil Modulen IBD Montelukast Montelukast Montelukast Montelukast Multiple Sclerosis (MS) Treatments Multiple Sclerosis (MS) Treatments Multiple sclerosis (MS) treatments

<100 1,000-10,000 50,000+ 100-1000 10,000-50,000 10,000-50,000 10,000-50,000 10,000-50,000 1,000-10,000 10,000-50,000 1,000-10,000 1,000-10,000 1,000-10,000 1,000-10,000 1,000-10,000 1,000-10,000 1,000-10,000 1,000-10,000 50,000+ 100-1000 100-1000 100-1000

5

---

Pharmaceutical Multiple Sclerosis (MS) treatments

Funding Requested For Multiple Sclerosis (MS) - Amending treatment switching criteria Prophylaxis of acute transplant rejection in patients receiving allogeneic renal transplants Maroteaux-Lamy syndrome (Mucopolysaccharidosis VI, MPS VI), Enzyme replacement therapy (ERT) Amending access criteria for alcohol dependence Henoch-Schonlein purpura (low dose) Acute migraine Cystic fibrosis Hypercholesterolaemia and mixed dyslipidaemia Chronic Myeloid Leukaemia - after failure of imatinib Contraception Acromegaly - where surgery is contraindicated or awaiting effects of radiotherapy Acromegaly - presurgery TSH-producing pituitary adenomas Nausea and vomiting from malignant bowel obstruction Schizophrenia- second line for patients who have failed on risperidone depot Schizophrenia Severe allergic asthma Paediatric patients who cannot take oral tablet formulations Malnutrition Malnutrition Oral supplement Malnutrition and physical frailty Epilepsy - second line after carbamazepine Urinary incontinence Low energy feed required Disease related malnutrition

Patient Population 100-1000

Mycophenolate

<100

Naglazyme

<100

Naltrexone Naltrexone Naratriptan Nebulised hypertonic saline Niacin + laropiprant (extended release) Nilotinib Non-latex condoms Octreotide Octreotide Octreotide Octreotide Olanzapine depot Olanzapine depot injection Omalizumab Orablend Oral feed (Fortijuce) Oral nutrient feed (fortisip compact) Oral supplement 1 Kcal/ml Oral supplement powder (Enprocal) Oxcarbazepine Oxybutynin patches (transdermal) Paediatric enteral feed - 0.75 kcal/ml with fibre RTH (Nutrini Low Energy Multi Fibre) Paediatric enteral feed 1.5 kcal with fibre RTH (Nutrini Energy Multi Fibre)

1,000-10,000 <100 10,000-50,000 100-1000 <100 <100 50,000+ <100 <100 <100 <100 100-1000 1,000-10,000 100-1000 50,000+ 1,000-10,000 1,000-10,000 1,000-10,000 1,000-10,000 1,000-10,000 1,000-10,000 1,000-10,000 1,000-10,000

6

---

Pharmaceutical Paliperidone palmitate depot injection Paliperidone tablets Palivizumab Paracetamol 500mg with codeine 30mg Paediatric oral feed 1 kcal/ml in 100ml Ready to Feed bottle (Infatrini) Pegylated liposomal doxorubicin Pemetrexed disodium Pipobroman PKU Gel Potassium citrate Pramipexole Prasugrel Protein drink - PKU cooler 10mg,15mg, 20mg Protein drink MSUD Quetiapine extended-release tablets Raloxifene Raloxifene Ranibizumab Riluzole Risedronate Risedronate Rituximab Rituximab

Funding Requested For Schizophrenia Schizophrenia second-line to risperidone or quetiapine Prevention of respiratory syncytial virus (RSV) infection in high risk infants Pain Infants with increased nutritional requirements Advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy Non Small Cell Lung Cancer (NSCLC) Polycythaemia and essential thrombocythaemia Phenylketonuria (PKU) Recurrent calcium oxalate urolithiasis Parkinson's disease Acute Coronary Syndrome (ACS) with Percutaneous Coronary Intervention (PCI) Phenylketonuria (PKU) Maple Syrup Urine Disease Schizophrenia and bipolar disorder Osteoporosis - first line Osteoporosis in patients intolerant to bisphosphonates Wet age-related macular degeneration Amyotrophic lateral sclerosis Osteoporosis - first line Paget's disease Chronic Lymphocytic Leukaemia (CLL) first line Large cell lymphoma pts who have relapsed following prior non rituximab therapy Relapsed Chronic Lymphocytic Leukaemia - previously treated with rituximab Relapsed Chronic Lymphocytic Leukaemia - rituximab naïve

Patient Population 1,000-10,000 1,000-10,000 10,000-50,000 50,000+ 1,000-10,000

100-1000 <100 <100 <100 100-1000 1,000-10,000 1,000-10,000 <100 <100 1,000-10,000 10,000-50,000 1,000-10,000 1,000-10,000 100-1000 10,000-50,000 1,000-10,000 <100 <100

Rituximab Rituximab

<100 <100

7

---

Pharmaceutical Rituximab Rituximab Rivaroxaban Rivastigmine capsules Rivastigmine patches Rosuvastatin Sertraline Sibutramine Sildenafil Sildenafil Sildenafil

Funding Requested For Indolent Non-Hodgkins Lymphoma (NHL) - retreatment Large cell lymphoma - patients who have relapsed following prior rituximab therapy Prevention of venous thrombosis following orthopaedic surgery Alzheimer's disease (Dementia) Alzheimer's disease (Dementia) Hypercholesterolemia - third-line statin therapy Depression Obesity Pulmonary arterial hypertension (PAH) secondary to other lung disease Post-Fontan Repair Pulmonary arterial hypertension (PAH) secondary to congenital diaphragmatic hernia (CDH) Pulmonary Arterial Hypertension (PAH) secondary to chronic lung disease (CLD) Type 2 diabetes Type 2 diabetes Hepatocelluar carcinoma Renal Cell Carcinoma Osteoporosis - second line following bisphosphonates Renal cell carcinoma Gastrointestinal Stromal Tumour (GIST) Benign prostatic hyperplasia (BPH) in patients intolerant to alpha-blockers Hypertension Anaplastic astrocytoma Glioblastoma multiforme Hepatitis B - Post liver transplant HIV infection HIV infection Osteoporosis - second-line following bisphosphonates Testosterone deficiency Multiple myeloma, first line for stem cell transplant ineligible

Patient Population 100-1000 <100 1,000-10,000 10,000-50,000 1,000-10,000 1,000-10,000 10,000-50,000 50,000+ 100-1000 <100 <100

Sildenafil Sitagliptin Sitagliptin and Metformin Sorafenib Sorafenib Strontium ranelate Sunitinib Sunitinib Tamsulosin Telmisartan Temozolomide Temozolomide Tenofovir Tenofovir, emtricitabine Tenofovir, emtricitabine, efavirenz Teriparatide Testosterone undecanoate injection Thalidomide

<100 10,000-50,000 10,000-50,000 100-1000 <100 1,000-10,000 <100 <100 1,000-10,000 50,000+ <100 <100 <100 1,000-10,000 1,000-10,000 1,000-10,000 100-1000 100-1000

8

---

Pharmaceutical Thalidomide Tolterodine and other formulations of oxybutynin (long acting and transdermal) Trastuzumab Travaprost and timolol Triamcinolone hexacetonide TYR Cooler, tyrosine and phenylalanine free protein substitute Varenicline Vildagliptin Vinorelbine (oral) Vitamin D Vitamin D and Calcium Zoledronic acid Zoledronic acid Zoledronic acid Zolmitriptan

Funding Requested For Multiple myeloma, Stem cell transplant eligible Overactive bladder Breast cancer - metastatic retreatment Glaucoma Intra-articular injection Tyrosinaemia Nicotine addiction Type 2 diabetes Non-Small Cell Lung Cancer (NSCLC) Vitamin D deficiency Vitamin D deficiency and osteoporosis Osteoporosis - first line Paget's disease Osteoporosis - second line following bisphosphonates Acute migraine

Patient Population 100-1000 50,000+ <100 1,000-10,000 10,000-50,000 <100 1,000-10,000 10,000-50,000 <100 10,000-50,000 10,000-50,000 10,000-50,000 1,000-10,000 1,000-10,000 10,000-50,000

9